140P Preliminary results from PROPEL: A phase I/II study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLC
Enriqueta Felip(Institut Català d'Ornitologia), Apar Kishor Ganti(University of Nebraska Medical Center), Óscar Juan(Hospital Universitari i Politècnic La Fe), Jonathan Zalevsky(Nektar Therapeutics (United States)), David R. Spigel(Sarah Cannon), Mehmet Altan(The University of Texas MD Anderson Cancer Center), David Chien(Nektar Therapeutics (United States)), Martin Reck(German Center for Lung Research), Delvys Rodríguez‐Abreu(Universidad de Las Palmas de Gran Canaria), Qiang Zhao(First Affiliated Hospital of Zhengzhou University), E. Späth‐Schwalbe(Vivantes Klinikum), Martin J. Edelman(Fox Chase Cancer Center), Susana Banerjee(Royal Marsden NHS Foundation Trust), Mary Tagliaferri(Nektar Therapeutics (United States)), Niels Reinmuth(Asklepios Fachkliniken München-Gauting), A. Reinacher-Schick(Universitätsklinikum Knappschaftskrankenhaus Bochum), J. Thaddeus Beck(Highlands Oncology Group), Daniel Johnson(Ochsner Medical Center), Sofia Chaudhry(Nektar Therapeutics (United States))
Cited by 1
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k